| 1st Apr 2019 7:00 am |
RNS |
Selumetinib gets Breakthrough Therapy Designation |
| 29th Mar 2019 5:15 pm |
RNS |
Results of Placing |
| 29th Mar 2019 7:00 am |
RNS |
Proposed placing of new ordinary shares |
| 29th Mar 2019 7:00 am |
RNS |
AZ and Daiichi Sankyo enter collaboration in novel |
| 27th Mar 2019 7:00 am |
RNS |
Forxiga approved in Japan for type-1 diabetes |
| 25th Mar 2019 7:00 am |
RNS |
Forxiga approved in Europe for type-1 diabetes |
| 18th Mar 2019 7:00 am |
RNS |
US FDA grants saracatinib ODD for IPF |
| 14th Mar 2019 12:00 pm |
RNS |
Notice of AGM |
| 12th Mar 2019 12:00 pm |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2019 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 5th Mar 2019 11:00 am |
RNS |
Annual Financial Report |
| 4th Mar 2019 4:04 pm |
RNS |
Holding(s) in Company |
| 1st Mar 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Mar 2019 1:45 pm |
RNS |
Lynparza receives positive EU CHMP opinion |
| 26th Feb 2019 7:00 am |
RNS |
Lynparza significantly delayed disease progression |
| 25th Feb 2019 7:00 am |
RNS |
Brilinta's PhIII THEMIS trial met primary endpoint |
| 14th Feb 2019 7:00 am |
RNS |
AstraZeneca Full-Year and Q4 2018 Results |
| 6th Feb 2019 7:00 am |
RNS |
US FDA grants Fasenra Orphan Drug Designation |
| 5th Feb 2019 7:05 am |
RNS |
US FDA grants Breakthrough Therapy Designation |
| 5th Feb 2019 7:00 am |
RNS |
EMA grants PRIME eligibility for MEDI8897 |
| 1st Feb 2019 3:00 pm |
RNS |
Total Voting Rights |
| 1st Feb 2019 1:17 pm |
RNS |
Forxiga receives positive EU CHMP opinion |
| 25th Jan 2019 2:00 pm |
RNS |
Completion of divestment of US Synagis rights |
| 7th Jan 2019 1:00 pm |
RNS |
AstraZeneca announces organisational changes |
| 2nd Jan 2019 3:00 pm |
RNS |
Total Voting Rights |
| 20th Dec 2018 1:47 pm |
RNS |
Bevespi Aerosphere approved in the EU for COPD |
| 20th Dec 2018 7:05 am |
RNS |
Lynparza meets primary endpoint in SOLO-3 trial |
| 20th Dec 2018 7:00 am |
RNS |
Phase III ROCKIES and OLYMPUS roxadustat trials |
| 19th Dec 2018 6:31 pm |
RNS |
FDA approves Lynparza as 1L maintenance therapy |
| 18th Dec 2018 9:09 am |
RNS |
Roxadustat approved in China for the treatment of |
| 14th Dec 2018 7:00 am |
RNS |
Directorate Change |
| 7th Dec 2018 7:00 am |
RNS |
Update on the Phase III EAGLE trial of Imfinzi |
| 6th Dec 2018 7:00 am |
RNS |
Divestment of rights to Covis completed |
| 4th Dec 2018 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 3rd Dec 2018 4:00 pm |
RNS |
Block listing Interim Review |
| 3rd Dec 2018 4:00 pm |
RNS |
Total Voting Rights |
| 3rd Dec 2018 7:00 am |
RNS |
Grünenthal Agreement for Nexium, Vimovo Completed |
| 26th Nov 2018 7:00 am |
RNS |
US FDA grants Fasenra ODD for EGPA |
| 16th Nov 2018 7:00 am |
RNS |
AstraZeneca provides update on Phase III MYSTIC |
| 13th Nov 2018 7:00 am |
RNS |
AstraZeneca to divest US Synagis rights to Sobi |
